Literature DB >> 8190623

DNA sequence specificity of mitoxantrone.

C Panousis1, D R Phillips.   

Abstract

An in vitro transcription assay was used to determine the sequence specificity of binding of mitoxantrone to a 497 bp fragment of DNA containing the lac UV5 promoter. Transcriptional blockages of the E. coli RNA polymerase were observed dominantly prior to 5'-CpA sequences (64% occurrence), and to a lesser extent 5'-CpG sequences (29%). Overall, 93% of all blockage sites were prior to pyrimidine (3'-5') purine sequences. An effect of flanking sequences was evident since the blockage sites contained an A/T base pair 5' prior to the consensus CpA and CpG intercalation sites. The consensus sequences for the preferred mitoxantrone intercalation sites are therefore 5'-(A/T)CA and 5'-(A/T)CG. The location of transcriptional blockages one base pair prior to the intercalation site is consistent with the fact that the mitoxantrone side chains lie in the major groove.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190623      PMCID: PMC307987          DOI: 10.1093/nar/22.8.1342

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  19 in total

1.  A theoretical investigation on the sequence selective binding of mitoxantrone to double-stranded tetranucleotides.

Authors:  K X Chen; N Gresh; B Pullman
Journal:  Nucleic Acids Res       Date:  1986-05-12       Impact factor: 16.971

2.  Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.

Authors:  K M Tewey; G L Chen; E M Nelson; L F Liu
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

3.  Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo.

Authors:  B Sundman-Engberg; U Tidefelt; A Gruber; C Paul
Journal:  Leuk Res       Date:  1993-04       Impact factor: 3.156

4.  Comparison of the interaction of antineoplastic aminoanthraquinone analogs with DNA using competitive fluorescence polarization.

Authors:  J Roboz; C L Richardson; J F Holland
Journal:  Life Sci       Date:  1982-07-05       Impact factor: 5.037

5.  Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz; F Traganos; M R Melamed
Journal:  Biochem Pharmacol       Date:  1981-02-01       Impact factor: 5.858

6.  Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.

Authors:  J W Lown; C C Hanstock; R D Bradley; D G Scraba
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

7.  Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.

Authors:  R K Zee-Cheng; C C Cheng
Journal:  J Med Chem       Date:  1978-03       Impact factor: 7.446

8.  Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.

Authors:  M A Cornbleet; R C Stuart-Harris; I E Smith; R E Coleman; R D Rubens; M McDonald; H T Mouridsen; H Rainer; A T van Oosterom; J F Smyth
Journal:  Eur J Cancer Clin Oncol       Date:  1984-09

9.  DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio)vinylquinolinium iodides.

Authors:  W O Foye; O Vajragupta; S K Sengupta
Journal:  J Pharm Sci       Date:  1982-02       Impact factor: 3.534

10.  DNA sequence preferences for the anti-cancer drug mitoxanthrone and related anthraquinones revealed by DNase I footprinting.

Authors:  K R Fox; M J Waring; J R Brown; S Neidle
Journal:  FEBS Lett       Date:  1986-07-07       Impact factor: 4.124

View more
  2 in total

1.  Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts.

Authors:  B S Parker; S M Cutts; C Cullinane; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

2.  Disordering of human telomeric G-quadruplex with novel antiproliferative anthrathiophenedione.

Authors:  Dmitry Kaluzhny; Nikolay Ilyinsky; Andrei Shchekotikhin; Yuri Sinkevich; Philipp O Tsvetkov; Vladimir Tsvetkov; Alexander Veselovsky; Mikhail Livshits; Olga Borisova; Alexander Shtil; Anna Shchyolkina
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.